André Dupont

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy.

M. Koutsilieris, J. Goméz, F. Labrie, 1993, The Journal of urology.

LOSS OF LUTEINIZING HORMONE BIOACTIVITY IN PATIENTS WITH PROSTATIC CANCER TREATED WITH AN LHRH AGONIST AND A PURE ANTIANDROGEN

F. Labrie, R. St-Arnaud, S. Kelly, 1986, Clinical endocrinology.

Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.

P. Dupont, F. Labrie, S. Moorjani, 1991, The Journal of clinical endocrinology and metabolism.

Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.

F. Labrie, S. Moorjani, A. Bélanger, 1988, The Journal of clinical endocrinology and metabolism.

Serum prostate specific antigen as pre-screening test for prostate cancer.

J. Goméz, F. Labrie, L. Cusan, 1992, The Journal of urology.

Extremely rapid degradation of [3H] methionine-enkephalin by various rat tissues in vivo and in vitro.

F. Labrie, M. Garon, G. Alvarado-Urbina, 1977, Life sciences.

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.

F. Labrie, Y. Lacourciére, A. Bélanger, 1988, Journal of steroid biochemistry.

Organ distribution of radioactivity and disappearance of radioactivity from plasma after administration of (3H) luteinizing hormone-releasing hormone to mice and rats.

A. Schally, D. Coy, F. Labrie, 1974, Neuroendocrinology.